1. Introduction {#sec1}
===============

*Staphylococcus aureus* (*S. aureus*) is an etiologic agent for a wide range of illnesses from localized skin infections such as impetigo, furuncles, and cellulitis to life-threatening diseases such as pneumonia, meningitis, osteomyelitis, necrotizing fasciitis, endocarditis, toxic shock syndrome, and bacteremia \[[@B1]\]. Hospital-associated methicillin-resistant *S. aureus*(HA-MRSA) first appeared in 1961 shortly after the introduction of methicillin under the selective pressure of antibiotics \[[@B2], [@B3]\]. Since then, numerous MRSA clones have emerged and become a major cause of nosocomial infections throughout the world \[[@B5]--[@B6]\]. MRSA produces penicillin-binding protein 2′ (PBP2′) with a low affinity for *β*-lactam antibiotics. PBP2′ is encoded by the *mecA* gene, which is located on a large mobile genetic DNA element, the staphylococcal cassette chromosome *mec*(SCC*mec*) \[[@B7], [@B8]\]. Early MRSA clones were HA-MRSA isolated from patients with compromised immune systems under medical procedures. However, in 1993, community-associated MRSA (CA-MRSA) emerged in patients without risk factors in Western Australia \[[@B9]\]. CA-MRSA clones, which are distinct from HA-MRSA clones, have evolved differently in separate geographical areas and have spread in communities \[[@B10]\]. The incidence of infections due to CA-MRSA, including infections in children with no identifiable risk factors, has increased worldwide as a community pathogen \[[@B11], [@B12]\]. There are several types of CA-MRSA clones including ST1 (USA400) in Asia, Europe, and the US, ST8 (USA 300) in Europe and the US, ST30 in Australia, Europe, and South America, ST59 in Asia and the US, and ST80 (European clone) in Asia, Europe, and the Middle East. However, recent studies have shown that CA-MRSA strains are spreading into hospitals and are replacing traditional HA-MRSA strains \[[@B13], [@B14]\]. Therefore, distinction between the traditional HA-MRSA and CA-MRSA strains based on epidemiologic definitions has become difficult, and distinction based on the molecular typing is unclear \[[@B5], [@B15]\].

*S. aureus* is both a commensal organism and a pathogen. *S. aureus* colonized in the anterior nares, skin, and gastrointestinal tract plays an important role in transmission among individuals and in development of infection \[[@B16]\]. Hisata et al. and Ozaki et al. reported that the prevalences of nasal carriage of *S. aureus* in healthy Japanese children were 28.2% and 40.4%, respectively, and that the ratios of MRSA strains among the *S. aureus*isolates were 15.1% and 9.1%, respectively \[[@B17], [@B18]\]. Impetigo is a highly contagious infection of the superficial epidermis and is commonly caused by exfoliative toxins (ETs) of *S. aureus* \[[@B19]\]. The ratio of MRSA among *S. aureus* isolates from patients with impetigo between 1994 and 2000 was below 20% in Japan \[[@B20]\]. However, the ratio of MRSA has recently increased to 20 \~ 50% in Japan \[[@B21]--[@B24]\].

The characteristics of CA-MRSA strains in Japan are different from those reported in other countries. Although highly virulent CA-MRSA strains carrying Panton-Valentine leukocidin (PVL) genes have been spreading widely in the world, PVL-negative CA-MRSA has been disseminated in Japan \[[@B15], [@B17], [@B18], [@B23], [@B25]\]. The aim of this study was to investigate the molecular epidemiology by multilocus sequence typing (MLST) and staphylococcal cassette chromosome *mec*(SCC*mec*) typing and the antimicrobial susceptibilities of *S. aureus* isolates from children with impetigo.

2. Materials and Methods {#sec2}
========================

2.1. Bacterial Strains {#sec2.1}
----------------------

Samples were isolated from skin swabs taken from pediatric outpatients with impetigo. A total of 136 *S. aureus* isolates were collected from 136 different patients (69 males and 67 females; mean age: 3.8 years; SD: 2.3 years) with impetigo at private offices of 25 practicing pediatricians and 10 hospitals between June 2009 and June 2010 in Hokkaido, the northernmost island of Japan. All samples were collected after obtaining informed consent from the children\'s parents. MRSA strains were identified by polymerase chain reaction (PCR) for the *mecA* gene and by the detection of penicillin-binding protein 2′ (Denka Seiken, Co., Tokyo, Japan).

2.2. Molecular Typing and Virulence Gene Analysis {#sec2.2}
-------------------------------------------------

PCR primers used for molecular typing and virulence gene analysis in this study are listed in [Table 1](#tab1){ref-type="table"}. The presence of genes encoding PVL (*luk*S-PV-*luk*F-PV), toxic shock syndrome toxin 1 (TSST-1) (*tst*), and 2 ETs (ETA, ETB) (*eta*,*etb*) was examined by the PCR method using previously reported primers \[[@B26]\]. MRSA isolates were characterized by MLST as specific sequence types (STs) and clonal complexes (CCs) based on the DNA sequences at 7 defined loci. MLST was performed as described by Enright et al. \[[@B27]\]. MLST is based on sequence analysis of PCR products from seven *S. aureus*housekeeping genes, that is, *arcC, aroE, glpF, gmk, pta, tpi, and yqiL*. Each sequence was submitted to the MLST database website (<http://www.mlst.net/>) for the assignment of the allelic profile and ST. Different sequences are assigned distinct alleles of each housekeeping gene, and each isolate is defined by alleles of the seven genes. The ST data were further analyzed using eBURST (<http://eburst.mlst.net/>) to determine the CC. SCC*mec* typing was performed by the multiplex PCR method described by Kondo et al. SCC*mec* types (I to VI) were determined on the basis of the class (classes A, B, and C) of mec gene complex and the type (types 1, 2, 3, 4, and 5) of *ccr* gene complex \[[@B26]\]. Subtyping of SCC*mec* types II and IV was performed on the basis of different J1 regions by PCR using published primers \[[@B28]\].

2.3. Antimicrobial Susceptibility Testing {#sec2.3}
-----------------------------------------

For *in vitro* antimicrobial susceptibility testing, minimal inhibitory concentrations (MICs) of a panel of 12 antimicrobial drugs, that is, oxacillin (MPIPC), ampicillin (ABPC), cefaclor (CCL), cefditoren (CDTR), clarithromycin (CAM), clindamycin (CLDM), fosfomycin (FOM), minocycline (MINO), gentamicin (GM), vancomycin (VCM), nadifloxacin (NDFX), and fucidic acid (FA), were determined using a frozen plate (Eiken Chemical Co., Tokyo, Japan). This plate is based on the broth microdilution method recommended by the Japan Society for Chemotherapy (JSC) \[[@B29], [@B30]\]. The breakpoints for these antimicrobial agents were determined according to the interpretation criteria of Clinical and Laboratory Standards Institute (CLSI) \[[@B31], [@B32]\] and JSC \[[@B29], [@B30]\]. Susceptibilities to antimicrobial drugs for which breakpoints are not determined by CLSI and JSC were defined in this study. A nitrocefin method was used for *β*-lactamase detection \[[@B33]\].

3. Results {#sec3}
==========

In the bacteriological analysis of the 155 patients with impetigo, *S. aureus* and *Streptococcus pyogenes* were isolated from 136 and 6, respectively. Two cases involved two pathogens. No pathogenic organism was isolated from 15 patients. Of the 136 *S. aureus*cases, 122 (89.7%) were MSSA and 14 (10.3%) were MRSA. The 14 MRSA patients except for two newborns did not have a history of hospitalization during the previous year. Age distribution in the 136 patients was shown in [Table 2](#tab2){ref-type="table"}.

The molecular characteristics of the 14 MRSA strains isolated from the patients with impetigo were examined and are summarized in [Table 3](#tab3){ref-type="table"}. Among the 14 strains that carried the mec gene complex, 11 were determined the SCCmec element type. By SCC*mec* typing, the 14 MRSA strains were defined as SCC*mec* type II (IIb: 3 strains; II~NT~: 4 strains), type IVa (3 strains), type V (1 strain), and unknown type (3 strains). Types of *ccr* gene complex in 3 strains could not be determined.

The 14 MRSA strains were comprised of 4 CCs. The four CCs were CC89 (11/14), CC5 (1/14), CC8 (1/14), and CC121 (1/14). ST89, ST91, and ST2117 strains belonged to the same CC89. No PVL-positive strains were identified in the 14 MRSA strains. The MRSA strains belonging to ST5 and ST8 carried TSST-1. Of the 14 MRSA strains, 11 (78.6%) were *etb*gene positive, and one was *eta* gene positive. There was no strain carrying both *eta* and *etb* genes. The MRSA strains belonging to ST5 and ST8 were both *eta* gene- and *etb* gene-negative.

Antimicrobial susceptibilities of the MRSA and MSSA strains to 12 antimicrobial agents are summarized in [Table 4](#tab4){ref-type="table"}. The MICs of 12 antimicrobial agents for 14 individual MRSA strains are shown in [Table 5](#tab5){ref-type="table"}. *β*-Lactamase was produced by 99 (72.8%) of the 136 *S. aureus* isolates. Of the 122 MSSA isolates, 85 (69.7%) were *β*-lactamase producers. All MRSA isolates were *β*-lactamase-positive. MRSA strains were highly resistant to CCL, CDTR, and CLDM. GM- and CAM-resistant strains were frequently found in both MRSA and MSSA. MINO, NDFX, FA and VCM had significant antimicrobial activity against the *S. aureus* isolates. The ST5 MRSA strain exhibited resistance to multiple drugs, including MINO and NDFX.

4. Discussion {#sec4}
=============

The rate of CA-MRSA in patients with impetigo has been increasing in Japan. In this study, only 10.3% of the *S. aureus* isolates from patients with impetigo in Hokkaido, the northernmost island of Japan, were MRSA. The ratio of MRSA strains in Hokkaido is lower than those in other regions in recent studies \[[@B21]--[@B24]\]. This ratio of CA-MRSA in patients with impetigo in Hokkaido is similar to that in healthy children previously reported in Japan \[[@B17], [@B18]\]. However, further continuous surveillance is needed to clarify whether the low ratio of CA-MRSA in Hokkaido is true or due to biases.

HA-MRSA strains usually carry large SCC*mec* type I, II, or III and are usually multidrug resistant. On the other hand, CA-MRSA strains usually carry smaller SCC*mec* type IV or V and are usually more susceptible to non-*β*-lactam antibiotics \[[@B11], [@B34]\]. In previous studies, SCC*mec*type IV MRSA strains have been predominantly isolated from patients with impetigo \[[@B22], [@B35], [@B36]\]. Noguchi et al. reported that 98.7% of the MRSA strains isolated from patients with impetigo and staphylococcal scalded skin syndrome between 1999 and 2004 in Japan had type IV SCC*mec* \[[@B35]\]. Takizawa et al. reported that all of the characterized MRSA strains isolated from patients with impetigo in 2003 and 2004 also had type IV SCC*mec* \[[@B22]\]. Nakaminami et al. examined MRSA strains isolated from patients with impetigo in Japan in 2006 and reported that all isolates with SCC*mec*were classified into type IV (92.8%) and V (7.2%) \[[@B36]\]. MRSA strains isolated from children with impetigo in China from 2003 to 2007 were classified into type IV (54.5%), type V (18.2%), and VI (9.1%) \[[@B37]\].

However, in very recent studies, MRSA strains isolated from patients with impetigo had diverse SCC*mec* types, and SCC*mec* type IIb has been increasing \[[@B23], [@B24]\]. Type IIb SCC*mec*was first identified from MRSA strains isolated from healthy Japanese children \[[@B17]\]. Hisata et al. characterized 17 MRSA strains isolated from patients with impetigo at a Japanese hospital from June through August 2002. They found that the 17 MRSA strains carried diverse types of SCC*mec*: type II (IIb: 4 strains; unknown subtype: 2 strains), type IV (7 strains), and type V (4 strains) \[[@B23]\]. Shi et al. reported that among 26 MRSA strains isolated from patients with impetigo, 57.7% carried type IIa SCC*mec* element and 42.3% carried type IV SCC*mec*element \[[@B24]\]. In the present study, the MRSA strains isolated from patients with impetigo also had diverse SCC*mec* types, and SCC*mec* type II, including type IIb and II~NT~, was the predominant type among the CA-MRSA strains.

The role of PVL in the pathogenesis of staphylococcal infections is controversial \[[@B38]\]. However, PVL is responsible at least in part for the increased virulence of CA-MRSA. PVL-positive *S. aureus* strains are more frequently associated with cellulitis and abscesses than with impetigo \[[@B39]--[@B41]\]. In this study, none of the MRSA isolates carried the PVL gene. Although highly virulent CA-MRSA strains carrying PVL genes are known to prevail in the world, the prevalence of PVL-positive strains in Japan is not high \[[@B15], [@B17], [@B18], [@B23], [@B25]\]. There are three serological forms of ET, ETA, ETB, and ETD, which are linked to human impetigo \[[@B19]\]. The *eta* gene, encoding ETA, is located on a chromosome, whereas the *etb* gene, encoding ETB, is present on a plasmid. The **eta** and **etb** genes are generally found in **S. aureus** isolated from patients with impetigo. The *etb* gene is predominantly found in MRSA strains with **mecA*.*In this context, our data support previous data \[[@B21], [@B23], [@B24], [@B35], [@B36]\].

MLST is an excellent tool for investigating clonal evolution of MRSA. Six STs (ST5, ST8, ST89, ST91, ST121, and ST2117) were identified, and they were classified into four CCs (CC5, CC8, CC89, and CC121) in the present study. PVL-negative CA-MRSA strains, which belong to ST89 and ST91, have been associated with impetigo in Japanese children \[[@B22]--[@B24]\]. In this study, the most common ST in MRSA strains was also ST89 (57.1%), followed by ST91 (14.3%). ST89 and ST91 both belonged to the same CC89. We found that 11 of the 14 MRSA strains belonged to CC89 and carried diverse SCC*mec*types, IIb, II~NT~, Iva, and NT. Although one strain belonging to ST5, which has been commonly identified in HA-MRSA with type II SCC*mec*, was found in our MRSA isolates, it carried a nontypeable SCC*mec* element. The class of *mec* gene complex in the strain was class A, indicating that its SCC**mec** type should be a type other than type I, IV, V, VI, or VII \[[@B42]\]. In a previous study by Hisata et al. ST5 MRSA with SCC*mec* type IIa, which was indistinguishable from HA-MRSA strains (New York/Japan clone \[[@B4]\]) in Japan, accounted for 22.7% of MRSA strains isolated from healthy children \[[@B17]\]. Our ST5 MRSA strain was resistant to multiple drugs, including MINO and NDFX. Although ST8 MRSA strain with SCC*mec*type IVa \[[@B22], [@B43]\] and ST121 MRSA strain with SCC*mec*type V \[[@B44], [@B45]\] have been identified in CA-MRSA associated with impetigo, our MRSA strains with the same phenotypes did not carry PVL.

It is generally accepted that bacterial resistance to antimicrobial agents parallels the frequency of use of the agents. Unlike HA-MRSA, CA-MRSA is generally susceptible to non-*β*-lactam antibiotics, such as aminoglycosides, tetracyclines, and fluoroquinolones. However, *S. aureus* isolates from patients with impetigo were highly resistant to GM and CAM, reflecting frequent usage of GM ointment for the treatment of skin infections including impetigo and frequent usage of CAM for respiratory infection in Japan \[[@B20], [@B21], [@B35], [@B36]\].

5. Conclusions {#sec5}
==============

This study and a previous study indicated that PVL-negative CC89 strain with a marked divergence in SCC*mec* types predominated in Japanese communities, suggesting that it might be a Japanese domestic CA-MRSA clone. The existence of multiple types of SCC*mec* elements suggested that MRSA strains might be emerging locally in the community under the selective pressure of antibiotics. Furthermore, SCC*mec* II CA-MRSA may at least partially be beginning to replace SCC*mec* IVa CA-MRSA. Continuous monitoring of MRSA epidemiology using MLST and SCC*mec* typing and drug resistance trends would show change in the clonal distribution of MRSA, which may be crucial for the effective management of impetigo.
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###### 

List of primers.

  Gene                                           Primer name   Size of product (bp)   Primer sequence (5′→3′)           Reference
  ---------------------------------------------- ------------- ---------------------- --------------------------------- ------------
  \(1\) Detection of virulence gene                                                                                     \[[@B26]\]
  *lukS-PV-lukF-PV*                              luk-PV-1                             ATCATTAGGTAAAATGTCTGGACATGATCCA   
                                                 luk-PV-2      433                    GCATCAASTGTATTGGATAGCAAAAGC       
  *tst*                                          TST-1                                TTCACTATTTGTAAAAGTGTCAGACCCACT    
                                                 TST-2         180                    TACTAATGAATTTTTTTATCGTAAGCCCTT    
  *eta*                                          mpETA-1                              ACTGTAGGAGCTAGTGCATTTGT           
                                                 mpETA-3       190                    TGGATACTTTTGTCTATCTTTTTCATCAAC    
  *etb*                                          mpETB-1                              CAGATAAAGAGCTTTATACACACATTAC      
                                                 mpETB-2       621                    AGTGAACTTATCTTTCTATTGAAAAACACTC   
  \(2\) SCC*mec* typing                                                                                                 \[[@B28]\]
  \(i\) *ccr* gene complex type with*mecA*                                                                              
  *mecA*                                         mA1                                  TGCTATCCACCCTCAAACAGG             
                                                 mA2           286                    AACGTTGTAACCACCCCAAGA             
  Type 1                                         *α*1                                 AACCTATATCATCAATCAGTACGT          
                                                 *β*c          695                    ATTGCCTTGATAATAGCCITCT            
  Type 2                                         *α*2                                 TAAAGGCATCAATGCACAAACACT          
                                                 *β*c          937                    ATTGCCTTGATAATAGCCITCT            
  Type 3                                         *α*3                                 AGCTCAAAAGCAAGCAATAGAAT           
                                                 *β*c          1,791                  ATTGCCTTGATAATAGCCITCT            
  Type 4                                         *α*4.2                               GTATCAATGCACCAGAACTT              
                                                 *β*4.2        1,287                  TTGCGACTCTCTTGGCGTTT              
  type 5                                         *γ*F                                 CGTCTATTACAAGATGTTAAGGATAAT       
                                                 *γ*R          518                    CCTTTATAGACTGGATTATTCAAAATAT      
  \(ii\) *mec* gene complex class                                                                                       
  *mecA*                                         ml6                                  CATAACTTCCCATTCTGCAGATG           
                                                 mA7           1,963                  ATATACCAAACCCGACAACTACA           
  *mecB*                                         IS7                                  ATGCTTAATGATAGCATCCGAATG          
                                                 mA7           2,827                  ATATACCAAACCCGACAACTACA           
  *mecC (C2)*                                    mA7                                  ATATACCAAACCCGACAACTACA           
                                                 IS2(iS-2)     804                    TGAGGTTATTCAGATATTTCGATGT         
  \(iii\) SCC*mec* type II subtyping                                                                                    
  IIa (II.1)                                     kdpB2                                TAAACTGTGTCACACGATCCAT            
                                                 kdpB1         287                    GATTACTTCAGAACCAGGTCAT            
  IIb (II.2)                                     2b3                                  GCTCTAAAAGTTGGATATGCG             
                                                 2b4           1,518                  TGGATTGAATCGACTAGAATCG            
  IIE (II.3)                                     4b3                                  AACCAACAGTGGTTACAGCTT             
                                                 4b4           726                    CGGATTTTAGACTCATCACCAT            
  II.4                                           II4-3                                GTACCGCTGAATATTGATAGTGAT          
                                                 II4-1         2,003                  ACTCTAATCCTAATCACCGAAC            
  \(iv\) SCC*mec* type IV subtyping                                                                                     
  IVa (IV.1)                                     4al                                  TTTGAATGCCCTCCATGAATAAAAT         
                                                 4a3           458                    AGAAAAGATAGAAGTTCGAAAGA           
  IVb (IV.2)                                     4b3                                  AACCAACAGTGGTTACAGCTT             
                                                 4b4           726                    CGGATTTTAGACTCATCACCAT            
  IVc (IV.3)                                     4c5                                  ATCCATTTCTCAGGAGTTAG              
                                                 4c4           259                    AGGAAATCGATGTCATTATAA             
  IVd (IV.4)                                     4d3                                  AATTCACCCGTACCTGAGAA              
                                                 4d4           1,242                  AGAATGTGGTTATAAGATAGCTA           
  \(3\) Multilocus sequence typing (MLST)                                                                               \[[@B27]\]
  carbamate kinase (*arcC*)                      arcC-Up                              TTGATTCACCAGCGCGTATTGTC           
                                                 arcC-Dn       456                    AGGTATCTGCTTCAATCAGCG             
  Shikimate dehydrogenase (*aroE*)               aroE-Up                              ATCGGAAATCCTATTTCACATTC           
                                                 aroE-Dn       456                    GGTGTTGTATTAATAACGATATC           
  Glycerol kinase (*glpF*)                       glpF-Up                              CTAGGAACTGCAATCTTAATCC            
                                                 glpF-Dn       465                    TGGTAAAATCGCATGTCCAATTC           
  Guanylate kinase (*gmk*)                       gmk-Up                               ATCGTTTTATCGGGACCATC              
                                                 gmk-Dn        429                    TCATTAACTACAACGTAATCGTA           
  Phosphate acetyltransferase *(pta*)            pta-Up                               GTTAAAATCGTATTACCTGAAGG           
                                                 pta-Dn        474                    GACCCTTTTGTTGAAAAGCTTAA           
  Triosephosphate isomerase (*tpi*)              tpi-Up                               TCGTTCATTCTGAACGTCGTGAA           
                                                 tpi-Dn        402                    TTTGCACCTTCTAACAATTGTAC           
  Acetyl coenzyme A acetyltransferase *(yqiL*)   yqiL-Up                              CAGCATACAGGACACCTATTGGC           
                                                 yqiL-Dn       516                    CGTTGAGGAATCGATACTGGAAC           

###### 

Age distribution in the 136 patients.

  Age (years)   MSSA   MRSA   Total
  ------------- ------ ------ -------
  *＜*1         13     2      15
  1--\<2        19     2      21
  2--\<3        16     5      21
  3--\<4        16     2      18
  4--\<5        15     1      16
  5--\<6        17     0      17
  6--\<7        15     2      17
  7--\<12       11     0      11
                              
  Total         122    14     136

###### 

Molecular characterization of 14 MRSA strains isolated from patients with impetigo.

  Strain   Age            SCC*mec* typing   MLST   Presence of exotoxin genes                                                     
  -------- -------------- ----------------- ------ ---------------------------- ------ ----- ---------------------- --- ---- ---- ----
  T-11     1 yr           IIb               2      A                            2117   89    1-310-28-18-18-33-50   −   −    −    \+
  T-33     6 yrs 4 mos    IVa               2      B                            91     89    1-26-28-18-18-54-50    −   −    −    \+
  T-55     2 yrs 6 mos    NT                NT     A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-64     2 yra 6 mos    II~NT~            2      A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-71     6 yrs 6 mos    IIb               2      A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-79     3 yrs 10 mos   IVa               2      B                            91     89    1-26-28-18-18-54-50    −   −    −    \+
  T-83     3 yrs 11 mos   II~NT~            2      A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-114    2 yrs 3 mos    NT                NT     A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-119    2 yrs 2 mos    NT                NT     A                            5      5     1-4-1-4-12-1-10        −   \+   −    −
  T-125    4 yrs          V                 5      C2                           121    121   6-5-6-2-7-14-5         −   −    \+   −
  T-132    19 ds          II~NT~            2      A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-137    1 yr 1 mo      IIb               2      A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-139    10 ds          II~NT~            2      A                            89     89    1-26-28-18-18-33-50    −   −    −    \+
  T-144    2 yrs 1 mo     IVa               2      B                            8      8     3-3-1-1-4-4-3          −   \+   −    −

NT: nontypeable.

###### 

Comparison of antimicrobial susceptibilities of MRSA and MSSA.

  Antimicrobial agent   Resistance breakpoint (*μ*g/mL)   MSSA (*n* = 122)   MRSA (*n* = 14)                                  
  --------------------- --------------------------------- ------------------ ----------------- ------ -------------- -------- ------
  MPIPC                 4                                 ≦2                 ≦2                0      4--\>8         \>8      100
  ABPC                  0.5                               ≦0.12  5--\>16     16                71.3   4--\>16        \>16     100
  CCL                   16                                1--16              4                 1.6    4--\>16        \>16     92.9
  CDTR                  2\*                               0.5 --2            1                 0.8    2--\>16        \>16     100
  CAM                   4                                 ≦0.125--\>16       \>16              67.2   \>16           \>16     100
  CLDM                  1                                 ≦0.125--0.25       0.25              0      ≦0.125--\>16   \>16     71.4
  FOM                   8\*\*                             0.25--\>16         16                20.5   1--\>16        8        14.3
  MINO                  8                                 ≦0.125--0.25       ≦0.125            0      ≦0.125--16     0.25     7.1
  GM                    8                                 0.25--\>16         \>16              54.1   1--\>16        \>16     92.9
  VCM                   4                                 ≦0.5--1            1                 0      1-2            1        0
  NDFX                  4\*\*                             ≦0.125--2          ≦0.125            0      ≦0.125--\>16   ≦0.125   7.1
  FA                    2\*\*                             ≦0.125--\>16       0.5               0.82   ≦0.125--1      0.5      0

The breakpoints for these antimicrobial agents were determined according to the interpretation criteria of Clinical and Laboratory Standards Institute (CLSI). Susceptibility to antimicrobial drugs for which breakpoints are not determined by CLSI was according to the interpretation criteria of the Japan Society for Chemotherapy (\*) or defined in this study (\*\*).

###### 

Antimicrobial susceptibilities of 14 MRSA strains.

  Strain   MIC (*μ*g/mL) of antimicrobial agents                                                                            
  -------- --------------------------------------- ------ ------ ------ ------ -------- ------ -------- ------ --- -------- --------
  T-11     \>8                                     \>16   \>16   \>16   \>16   \>16     1      ≦0.125   \>16   2   ≦0.125   0.25
  T-33     \>8                                     16     \>16   4      \>16   \>16     2      ≦0.125   \>16   1   ≦0.125   0.25
  T-55     \>8                                     16     \>16   8      \>16   \>16     4      0.25     \>16   1   ≦0.125   0.25
  T-64     \>8                                     \>16   \>16   \>16   \>16   \>16     2      ≦0.125   \>16   1   ≦0.125   0.25
  T-71     \>8                                     16     16     4      \>16   \>16     2      ≦0.125   \>16   1   ≦0.125   ≦0.125
  T-79     \>8                                     16     \>16   4      \>16   ≦0.125   4      ≦0.125   \>16   1   ≦0.125   0.25
  T-83     \>8                                     16     \>16   4      \>16   \>16     2      0.25     \>16   1   ≦0.125   ≦0.125
  T-114    \>8                                     16     \>16   16     \>16   \>16     1      ≦0.125   \>16   1   ≦0.125   0.25
  T-119    \>8                                     \>16   \>16   \>16   \>16   ≦0.125   \>16   16       \>16   1   \>16     0.5
  T-125    4                                       4      4      2      \>16   0.25     4      ≦0.125   \>16   1   ≦0.125   0.25
  T-132    \>8                                     16     \>16   16     \>16   \>16     2      ≦0.125   \>16   1   ≦0.125   ≦0.125
  T-137    \>8                                     \>16   \>16   \>16   \>16   \>16     2      ≦0.125   \>16   1   ≦0.125   1
  T-139    \>8                                     16     \>16   16     \>16   \>16     2      ≦0.125   \>16   1   ≦0.125   0.25
  T-144    \>8                                     16     \>16   16     \>16   ≦0.125   8      ≦0.125   1      1   ≦0.125   0.25

[^1]: Academic Editor: Hans Juergen Laws
